Aprepitant

Generic Name
Aprepitant
Brand Names
Aponvie, Cinvanti, Emend
Drug Type
Small Molecule
Chemical Formula
C23H21F7N4O3
CAS Number
170729-80-3
Unique Ingredient Identifier
1NF15YR6UY
Background

Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...

Indication

For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).

Associated Conditions
Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
Associated Therapies
-
Clinical Trials
Related News

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents

First Posted Date
2010-11-25
Last Posted Date
2017-04-19
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
4
Registration Number
NCT01249001
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

Comparison of Adding EMEND to PONV/PDNV Treatment Regimen

Not Applicable
Withdrawn
Conditions
Postoperative Nausea and Vomiting
Interventions
Drug: aprepitant
First Posted Date
2010-08-20
Last Posted Date
2024-08-30
Lead Sponsor
University of Nebraska
Registration Number
NCT01186029

Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study

First Posted Date
2010-08-17
Last Posted Date
2019-10-09
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
19
Registration Number
NCT01183481
Locations
🇨🇦

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial

Phase 2
Completed
Conditions
Gastroparesis
Interventions
Drug: Placebo
Drug: Aprepitant
First Posted Date
2010-06-23
Last Posted Date
2019-05-08
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
126
Registration Number
NCT01149369
Locations
🇺🇸

Temple University Hospital, Philadelphia, Pennsylvania, United States

🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

and more 5 locations

Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer

Not Applicable
Withdrawn
Conditions
Ovarian Cancer
Interventions
Drug: Aprepitant
First Posted Date
2009-11-23
Last Posted Date
2015-03-18
Lead Sponsor
NYU Langone Health
Registration Number
NCT01017809
Locations
🇺🇸

NYU Clinical Cancer Center, New York, New York, United States

Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy

Phase 2
Completed
Conditions
Nausea
Vomiting
Interventions
Drug: aprepitant
Drug: Ondansetron
First Posted Date
2009-09-03
Last Posted Date
2017-12-05
Lead Sponsor
University of Vermont
Target Recruit Count
52
Registration Number
NCT00970905
Locations
🇺🇸

Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

🇺🇸

Fletcher Allen Health Care, Burlington, Vermont, United States

🇺🇸

Mayo Clinic Arizona, Scottsdale, Arizona, United States

Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients

Not Applicable
Completed
Conditions
Vomiting
Nausea
Interventions
Drug: Aprepitant placebo
Drug: Aprepitant
First Posted Date
2009-08-11
Last Posted Date
2012-02-16
Lead Sponsor
University of Pennsylvania
Target Recruit Count
125
Registration Number
NCT00956215
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

First Posted Date
2009-08-07
Last Posted Date
2015-06-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
100
Registration Number
NCT00954941
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

First Posted Date
2009-08-06
Last Posted Date
2017-06-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
421
Registration Number
NCT00952341

The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD

First Posted Date
2009-05-11
Last Posted Date
2015-11-03
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Target Recruit Count
58
Registration Number
NCT00896038
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy